8-K: Forte Biosciences Advances FB102, Reports Q2 Results

Forte Biosciences announced its second quarter 2025 financial results and provided updates on its FB102 clinical programs, with three key trial readouts expected in 2026.

Summary

• Forte Biosciences reported its second quarter 2025 financial results and provided a business update on its FB102 clinical programs.
• The company has initiated three clinical trials for FB102, with topline data readouts expected in 2026 for celiac disease (Phase 2), vitiligo (Phase 1b), and alopecia areata (Phase 1b).
• Positive results from the FB102 Phase 1b celiac disease trial were reported in June 2025, demonstrating statistically significant benefits in composite histology (VCIEL), IEL density, and a 42% symptom benefit compared to placebo.
• Forte Biosciences ended Q2 2025 with $106.1 million in cash and cash equivalents, a significant increase from $22.2 million at December 31, 2024.
• Net proceeds from a public offering in June 2025 and an over-allotment exercise in July 2025 totaled $71.6 million.
• Research and development expenses increased to $8.6 million for Q2 2025 from $5.7 million in Q2 2024, primarily due to increased clinical trial activity.
• General and administrative expenses decreased to $3.0 million for Q2 2025 from $7.1 million in Q2 2024, mainly due to lower professional and legal expenses.
• Net loss per share improved to $(0.96) for Q2 2025 compared to $(6.78) for Q2 2024.

Sentiment

Score: 8

Explanation: The company reported positive Phase 1b clinical data for FB102 in celiac disease, which is a significant de-risking event for a clinical-stage asset. The successful capital raise has substantially strengthened its balance sheet, providing a solid runway for advancing multiple clinical programs into 2026. The reduction in net loss per share and G&A expenses also indicates improved operational efficiency. However, the company remains pre-revenue with increasing R&D expenses, and future success hinges on positive outcomes from upcoming clinical trials.

Positives

• Positive Phase 1b clinical trial results for FB102 in celiac disease, demonstrating statistically significant benefits in composite histology (VCIEL, p=0.0099), IEL density (p=0.0035), and a 42% reduction in gluten challenge symptoms.
• FB102 was generally safe and well-tolerated in the celiac disease Phase 1b study, with only 3.1% of subjects experiencing Grade 3 (severe) adverse events, all from the placebo group.
• Strong cash position of $106.1 million as of June 30, 2025, providing runway for ongoing clinical development.
• Successful capital raise of $71.6 million in June and July 2025, significantly bolstering financial resources.
• Advancement of FB102 into Phase 2 for celiac disease and Phase 1b for vitiligo and alopecia areata, targeting multi-billion dollar potential market opportunities.
• FB102's unique mechanism of action (anti-CD122 antibody) targets both IL-2 and IL-15, potentially offering advantages over single-cytokine inhibitors or JAK inhibitors with black box warnings.
• Significant improvement in net loss per share for Q2 2025 to $(0.96) from $(6.78) in Q2 2024.
• Reduction in general and administrative expenses by $4.1 million in Q2 2025 compared to Q2 2024, primarily due to lower legal and professional fees.

Negatives

• The company continues to incur net losses, with a net loss of $(11.2) million for Q2 2025 and $(26.9) million for the six months ended June 30, 2025.
• Research and development expenses increased significantly to $8.6 million in Q2 2025, indicating a higher burn rate as clinical trials advance.
• The company is still in clinical stages, with no approved products and all key data readouts for FB102 expected in 2026, implying no near-term revenue generation from product sales.
• The increase in outstanding shares due to the public offering could lead to dilution for existing shareholders.

Risks

• Ability to obtain sufficient additional capital to continue advancing FB102 through its clinical development programs.
• Uncertainties associated with the clinical development and regulatory approval of FB102, including potential delays in the commencement, enrollment, and completion of clinical trials.
• The risk that results from preclinical studies and interim results of ongoing clinical trials may not be predictive of future results from later-stage clinical trials.
• Risks associated with the failure to realize any value from FB102 due to inherent risks, expense, and difficulties involved in successfully bringing product candidates to market.
• Fluctuations in professional and advisory fees may impact general and administrative expenses as the company builds out its infrastructure and pursues additional autoimmune indications.
• Regulatory scrutiny of the JAK class of inhibitors, which have demonstrated efficacy in vitiligo and alopecia areata, could impact the competitive landscape and market acceptance of new therapies.

Future Outlook

Forte Biosciences anticipates a very eventful 2026 with three key clinical trial readouts for its FB102 program: topline results from the Phase 2 celiac disease study, Phase 1b vitiligo study, and Phase 1b alopecia areata study. The company expects to initiate a Phase 1b trial for alopecia areata in the second half of 2025 and a Phase 2 trial for Type 1 Diabetes in 2026. Research and development expenses are projected to increase as FB102 advances through these clinical stages.

Management Comments

• "I am deeply appreciative of the Forte team's incredible accomplishments in initiating 3 clinical trials for FB102 with data readouts shortly."
• "We have begun dosing subjects in the FB102 phase 2 celiac disease clinical trial and look forward to reporting topline results from that study in 2026."
• "Based on the strength of the positive results from the FB102 phase 1b CeD trial, which we reported in June, we look forward to the phase 2 data further validating FB102 for the treatment of celiac disease."
• "With 3 key clinical trial readouts for FB102, 2026 will be a very eventful year and further highlight FB102's potential to address the significant unmet medical needs across multiple indications including celiac disease, vitiligo and alopecia areata, which represent multi-billion dollar potential market opportunities."

Industry Context

Forte Biosciences operates in the highly competitive biopharmaceutical sector, specifically targeting autoimmune and autoimmune-related diseases. The company's focus on FB102, an anti-CD122 antibody, positions it in a therapeutic area where existing treatments, such as JAK inhibitors for vitiligo and alopecia areata, face regulatory scrutiny and black box warnings. This creates a significant unmet need for safer and effective therapies, which FB102 aims to address with its unique dual IL-2/IL-15 inhibition mechanism. The celiac disease market also lacks approved therapies, offering a substantial opportunity for a novel treatment. The company's strategy to pursue multiple indications (celiac disease, vitiligo, alopecia areata, Type 1 diabetes) with a single product candidate (FB102) aligns with a "pipeline-in-a-product" approach, common in biotech to maximize asset value.

Comparison to Industry Standards

• FB102's mechanism of action, targeting both IL-2 and IL-15, offers a differentiated approach compared to single-cytokine inhibitors or JAK inhibitors. For instance, in vitiligo and alopecia areata, JAK inhibitors like ritlecitinib (LITFULO) and baricitinib (Olumiant) carry black box warnings, which FB102 aims to avoid by not being a JAK inhibitor.
• In celiac disease, where no approved therapies exist, FB102's positive Phase 1b results showing significant histological and symptom benefits position it favorably against other investigational immunomodulators or gluten modification strategies like IMGX-003 or CNP-101/TAK-101, which may target only one pathway (e.15).
• For Type 1 Diabetes, current approved treatments like LANTIDRA and TZIELD have significant safety challenges (e.g., 90% serious AEs for LANTIDRA, severe AEs for TZIELD) and high costs ($300K/cycle for LANTIDRA, $190K/cycle for TZIELD). FB102's in vitro data suggesting direct impact on T-cells and prevention of beta-cell killing could offer a safer and more targeted alternative.
• The company's cash position of $106.1 million after a capital raise is robust for a clinical-stage biotech, providing a runway for upcoming trials, though continued capital raises are typical for companies at this stage.

Stakeholder Impact

• Shareholders: Potential for value appreciation if clinical trials are successful, but also dilution from recent capital raise and ongoing losses.
• Patients (Celiac Disease, Vitiligo, Alopecia Areata, Type 1 Diabetes): Potential for novel, safer, and effective treatment options for diseases with significant unmet needs or limitations in existing therapies.
• Employees: Continued employment and potential growth opportunities as clinical programs advance.
• Investment Professionals/Analysts: New data and clinical milestones provide updated information for valuation and analysis.

Next Steps

• Present Phase 1b celiac disease data at the Tampere Celiac Disease Symposium (September 10-12, 2025).
• Continue dosing subjects in the FB102 Phase 2 celiac disease clinical trial, with topline results expected in 2026.
• Continue enrollment in the FB102 Phase 1b vitiligo clinical study, with topline data expected in 1H26.
• Initiate a Phase 1b trial in alopecia areata in 2H25, with topline data expected in 2026.
• Expect US IND for FB102 celiac disease Phase 2 trial in late 2025/early 2026.
• Initiate a Phase 2 trial for Type 1 Diabetes in 2026.
• Advance FB102 through Phase 2 celiac disease and Phase 1b vitiligo clinical trials, and commence a Phase 1b clinical trial for alopecia areata.

Key Dates

Recommendation

Forte Biosciences has reported positive Phase 1b clinical data for FB102 in celiac disease, a significant de-risking event that validates its mechanism of action. The company has successfully raised substantial capital ($71.6 million), providing a strong financial runway to advance multiple clinical programs (celiac disease Phase 2, vitiligo Phase 1b, alopecia areata Phase 1b) with key data readouts expected in 2026. FB102 targets multi-billion dollar markets with unmet needs and offers a differentiated mechanism compared to competitors, particularly avoiding the black box warnings associated with JAK inhibitors. While the company remains pre-revenue and will continue to incur losses, the positive clinical momentum, robust cash position, and clear development pathway for multiple indications make it an attractive investment for long-term growth in the biopharmaceutical sector.

Keywords

Forte Biosciences, FBRX, FB102, Autoimmune disease, Celiac disease, Vitiligo, Alopecia areata, Type 1 diabetes, Clinical trial, Phase 1b, Phase 2, Biopharmaceutical, Anti-CD122 antibody, IL-2, IL-15, Financial results, Q2 2025, Capital raise, Drug development